gms | German Medical Science

21st Annual Meeting of the German Retina Society and 8th Symposium of the International Society of Ocular Trauma (ISOT)

German Retina Society
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Treatment of central retinal artery occlusion: Results of a multicenter randomized trial (EAGLE-Study)

Meeting Abstract

  • Nicolas Feltgen - Freiburg/Germany
  • D. Schmidt - Freiburg/Germany
  • B. Jurklis - Freiburg/Germany
  • C. Gall - Freiburg/Germany
  • J. Wanke - Freiburg/Germany
  • C. Schmoor - Freiburg/Germany
  • L. Solymosi - Freiburg/Germany
  • H. Brückmann - Freiburg/Germany
  • A. Neubauer - Freiburg/Germany
  • M. Schumacher - Freiburg/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V136

The electronic version of this article is the complete one and can be found online at:

Published: June 18, 2008

© 2008 Feltgen et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



For the EAGLE Study Group

Background: To compare the therapeutical efficiacy of local intraarterial fibrinolysis (LIF) versus conservative treatment in patients with an acute central retinal artery occlusion (CRAO) in a prospective, randomised and multicenter trial.

Method: The study was started in 2002. The most important inclusion criterias are: (1) age between 18 – 75 years, (2) CRAO not older than 20 hours and (3) visual acuity < 0.32. Primary study endpoint is the visual acuity before and 1 month after therapy.

Results: The first interim analysis showed similar visual results in both groups and further recruitment was not recommended. Therefore, the EAGLE trial was stopped. Both therapeutic strategies gave better results as compared to natural course. Until December 2007 84 patients of 17 medical centers in Germany, Switzerland and Austria could be included in the study.The final analysis will be finished in May 2008. The results of all 84 included patients will be presented.

Financial support: DFG and Boehringer Ingelheim Pharma KG